The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...

The Company also provided an update on key corporate, clinical, and regulatory development initiatives ... of the updated KDIGO guidelines and potential approval of the recently accepted sNDA to ...

Introduction An organ transplant is a surgical procedure replacing a damaged organ with a healthy one. Diagnostics for organ transplants are cl ...

# The Supreme Court yesterday approved the Securities Commission’s bid to relegate its $221.55m claim against FTX behind those of the insolvent crypto exchange’s clients and other victims.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Currently, there are no approved therapies for treating these rare adrenal tumors. With the FDA granting a priority review to the sNDA, a decision from the regulatory body is expected on May 26 ...

IceCure's IceSense3, its predecessor cryoablation system, already has regulatory approval in China. The indicated use for ProSense® in China, per the Company's regulatory filing application ...